Immunovant 

Yahoo Finance • yesterday

Breakthrough Pipelines Ignite Investor Excitement: Retatrutide, VERVE-102, NEO100, and More Set to Transform Medicine

DENVER, May 27, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology investors are entering one of the most catalyst-heavy clinical cycles in years as a wave of Phase 2 and Phase 3 programs begins reshaping expectations acros... Full story

Yahoo Finance • 5 days ago

What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge

Superstring Capital Management cut its stake in UroGen Pharma Ltd. (NASDAQ:URGN), selling 330,983 shares in the first quarter in an estimated $6.64 million trade based on average quarterly pricing, according to a May 14, 2026, SEC filing.... Full story

Yahoo Finance • 5 days ago

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally

Superstring Capital Management disclosed a new position in Vir Biotechnology(NASDAQ:VIR), acquiring 730,548 shares in the first quarter. The estimated transaction value was $5.82 million based on quarterly average pricing. What happened... Full story

Yahoo Finance • 8 days ago

Sector Update: Healthcare Stocks Mixed Late Afternoon

Healthcare stocks were mixed late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 8 days ago

Can a New Arthritis Drug Make Immunovant the Next Biotech Star?

Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences. Continue Reading... Full story

Yahoo Finance • 8 days ago

These Two Biotech Stocks Rocketed — And One Just Broke Out

Immunovant stock shot to a two-year high Wednesday on "highly compelling" results for its experimental rheumatoid arthritis treatment. Continue Reading... Full story

Yahoo Finance • 8 days ago

2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug

Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences. Continue Reading... Full story

Yahoo Finance • 8 days ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Roivant Sciences IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provi... Full story

Yahoo Finance • 9 days ago

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Target Corporation (TGT [https://seekingalpha.com/symbol/TGT]) * Lowe's Companies (LOW [https://seekingalpha.com/symbol/LOW]) * ZIM Integrated Shipping Services Ltd. (Z... Full story

Yahoo Finance • 10 days ago

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?

Key Points Initiated 1,446,375-share position in Beam Therapeutics; estimated trade size $40.13 million (quarterly average price). Quarter-end stake valued at $34.47 million, a net position change reflecting both trading and price movemen... Full story

Yahoo Finance • 10 days ago

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?

Key Points ADAR1 Capital Management added 829,963 shares of Crinetics Pharmaceuticals; estimated trade size $37.07 million based on quarterly average pricing. Quarter-end position value increased by $26.98 million, reflecting both trading... Full story

Yahoo Finance • 10 days ago

Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight

DelveInsight Business Research LLP The myasthenia gravis market size reached approximately USD 6 billion in 2025 across the 7MM and is growing at a robust CAGR of 9.1% during the forecast period. This remarkable growth is being underpinne... Full story

Yahoo Finance • 2 months ago

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Thursday afternoon with the NYSE Health Care Index dropping 0.6% an PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Sector Update: Health Care Stocks Softer Thursday Afternoon

Health care stocks declined Thursday afternoon, with the NYSE Health Care Index down 0.6% and the St PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Stocks Sink as President Trump Signals Iran War Will Drag On

The S&P 500 Index ($SPX) (SPY) today is down -1.13%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -1.15%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.53%.  June E-mini S&P futures (ESM26) are down -1.07%, and June E-mini Na... Full story

Yahoo Finance • 2 months ago

Immunovant falls on late-stage trial setback for TED therapy

[Stethoscope with the word Thyroid Disorders.] Fauzi Muda/iStock via Getty Images Immunovant (IMVT [https://seekingalpha.com/symbol/IMVT]) shares lost ~10% in the premarket on Thursday after the company, a subsidiary of Roivant Sciences (... Full story

Yahoo Finance • 2 months ago

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated greater levels of proptosis improvement fr... Full story

Yahoo Finance • 2 months ago

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

On February 17, 2026, Logos Global Management LP disclosed in a Securities and Exchange Commission filing that it bought 1,100,000 shares of Immunovant(NASDAQ:IMVT), an estimated $24.53 million trade based on quarterly average pricing. Lo... Full story

Yahoo Finance • 3 months ago

Air Taxi Stock Archer Aviation Draws $22.5 Million Institutional Buy. Here's What Investors Should Know

On February 17, 2026, Alpine Global Management disclosed a buy of 2,392,026 shares of Archer Aviation(NYSE:ACHR), with an estimated transaction value of $22.51 million based on quarterly average pricing. What happened According to a Febr... Full story

Yahoo Finance • 3 months ago

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish

On February 17, 2026, Alpine Global Management disclosed a sale of 127,039 shares of Immunovant(NASDAQ:IMVT), with an estimated transaction value of $2.83 million based on quarterly average pricing. What happened According to a filing wi... Full story